XML 62 R16.htm IDEA: XBRL DOCUMENT v2.3.0.15
SEGMENT AND PRODUCT INFORMATION
9 Months Ended
Sep. 30, 2011
Notes To Consolidated Financial Statement Abstract 
SEGMENT AND PRODUCT INFORMATION

10.       SEGMENT AND PRODUCT INFORMATION

 

       The Company operates in one business segment: pharmaceuticals. The Company's current pharmaceutical franchises are divided between the dermatological and non-dermatological fields. The dermatological field represents products for the treatment of acne and acne-related dermatological conditions and non-acne dermatological conditions. The non-dermatological field represents products for the treatment of urea cycle disorder and contract revenue. The acne and acne-related dermatological product lines include SOLODYN® and ZIANA®. During early 2011, the Company discontinued its TRIAZ® branded products and decided to no longer promote its PLEXION® branded products. The non-acne dermatological product lines include DYSPORT®, LOPROX®, PERLANE®, RESTYLANE® and VANOS®. The non-dermatological product lines include AMMONUL® and BUPHENYL®. The non-dermatological field also includes contract revenues associated with licensing agreements and authorized generics.

 

       The Company's pharmaceutical products, with the exception of AMMONUL® and BUPHENYL®, are promoted to dermatologists and plastic surgeons. Such products are often prescribed by physicians outside these two specialties, including family practitioners, general practitioners, primary-care physicians and OB/GYNs, as well as hospitals, government agencies, and others. Currently, the Company's products are sold primarily to wholesalers and retail chain drug stores.

 

       Net revenues and the percentage of net revenues for each of the product categories are as follows (amounts in thousands):

 

 Three Months Ended Nine Months Ended 
 September 30,September 30, September 30,September 30, 
 20112010 20112010 
           
Acne and acne-related dermatological products$ 119,119$ 118,506 $ 345,711$ 363,483 
Non-acne dermatological products  55,659  49,499   165,599  124,767 
Non-dermatological products  9,890  9,091   29,098  27,984 
Total net revenues $ 184,668$ 177,096 $ 540,408$ 516,234 
           
  Three Months Ended Nine Months Ended
  September 30,September 30, September 30,September 30,
  20112010 20112010
           
Acne and acne-related dermatological products  65% 67%  64% 70%
Non-acne dermatological products  30  28   31  24 
Non-dermatological products  5  5   5  6 
Total net revenues   100% 100%  100% 100%